Clinical trials: Oral Anticoagulants
Patient Undergoing Diagnostic Coronary Angiography
Strategies to Maintain Radial Artery Patency Following Diagnostic Coronary Angiography - Subgroup of Patients on Oral Anticoagulants
To investigate whether omitting systemic anticoagulation during transradial coronary angiography and/or a distal radial access reduce the risk of postprocedural radial artery occlusion
- Trial name
- RAPID-2 (NCT04362020)
- Testing
- Distal radial access
- Volunteers
- 400 people
- Sponsor
- University of Luebeck
Healthcare Quality Indicators, Inappropriate Prescribing
Development and Validation of Automated Indicators on the Appropriateness of Oral Anticoagulant Prescriptions
This research focuses on the development and validation of indicators on the appropriateness of oral anticoagulant prescriptions.
- Conditions
- Healthcare Quality Indicators, Inappropriate Prescribing, Anticoagulant Drugs, Atrial Fibrillation
- Trial name
- PACHA (NCT02898090)
- Where
- 4 sites in France
- Volunteers
- 1,213 people
- Sponsor
- University Hospital, Bordeaux
Total Knee Arthroplasty, Venous Thromboembolism
Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty
Yes. For these two fields, I would enter the following in English, based on your study protocol. 1. Brief Summary Copy and paste: This study aims to compare three thromboprophylaxis regimens in adults undergoing primary total…
- Trial name
- DOLOTHROK (NCT07869615)
- Testing
- Apixaban, Rivaroxaban, Enoxaparin (LMWH)
- Where
- Tunisia
- Volunteers
- 138 people
- Sponsor
- Military Hospital of Tunis
Thrombosis
Pharmacogentic Screening of Coumarine Based Oral Anticoagulant Using Next Generation Seguencer
As drug response is a complex trait in the majority of cases using an optimal starting dose for an individual may reduce the time taken to reach a stable INR, and reduce the risk of having either a high INR (with a risk of…
- Trial name
- NCT03180567
- Testing
- Genetic Mutations
- Where
- Egypt
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tanta University
Ischemic Stroke, Patent Foramen Ovale
Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence
A patent foramen ovale (PFO) is found more frequently in patients with an ischemic stroke than in control subjects. Therapeutic options to prevent stroke recurrence include antiplatelet drugs, oral anticoagulants, and…
- Conditions
- Ischemic Stroke, Patent Foramen Ovale, Atrial Septal Aneurysm, Migraine
- Trial name
- CLOSE (NCT00562289)
- Testing
- aspirin, Antivitamins K or rivaroxaban or dabigatran or apixaban, Devices for PFO closure
- Where
- France
- Volunteers
- 664 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Venous Thromboembolism, Embolism and Thrombosis
Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)
The purpose of this study is to determine whether TTP889 prevents venous thromboembolism following surgery to repair hip fracture.
- Conditions
- Venous Thromboembolism, Embolism and Thrombosis, Hip Fractures
- Trial name
- NCT00119457
- Testing
- TTP889
- Where
- 21 sites in Czechia, Denmark and 2 more
- Volunteers
- 300 people
- Sponsor
- vTv Therapeutics
Atrial Fibrillation, Ischemic Stroke
Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs Warfarin)
The purpose of this study is to assess safety and effectiveness of direct oral anticoagulants (DOACs) and warfarin for stroke prevention in patients with non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Ischemic Stroke, Systemic Embolization, Major Bleed
- Trial name
- NCT03596502
- Testing
- Direct oral anticoagulants (DOACs), Warfarin
- Where
- Canada
- Volunteers
- 402,764 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Atrial Fibrillation
Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
1. The recent development of novel oral anticoagulants (NOACs), including direct thrombin inhibitor (dabigatran) and factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), could potentially overcome many drawbacks of…
- Trial name
- DARING-AF (NCT02666157)
- Testing
- Dabigatran etexilate, Rivaroxaban, Apixaban
- Where
- 5 sites in Taiwan
- Volunteers
- 3,672 people
- Sponsor
- National Cheng-Kung University Hospital
Myocardial Infarction, Acute, Left Ventricular Thrombus
Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF
APERITIF is a prospective randomized open-label, blinded end-point (PROBE) trial, nested in the ongoing the "FRENCHIE" registry, a French multicenter prospective observational study granted by "ANR-RHU Grand Emprunt", in which…
- Trial name
- APERITIF (NCT05077683)
- Testing
- Rivaroxaban 2.5 MG [Xarelto], DAPT strategy
- Where
- France
- Volunteers
- 560 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Emergency Care for Severe Bleeding While on Anticoagulants
Use of Prothrombin Complex Concentrate in Patients Admitted in Emergency Care Units for Severe Bleeding While Receiving Oral Anticoagulants
The study is assessing the impact of an expert eCRF on the management of severe bleeding in the administration of Prothrombin Complex Concentrate in patients treated with oral anticoagulants and adherence to recommendations or…
- Trial name
- NCT03320603
- Testing
- Expert eCRF, Prothrombin Complex Concentrate
- Where
- 26 sites in France
- Volunteers
- 397 people
- Sponsor
- Octapharma
Coronary Artery Disease
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Clopidogrel is the P2Y12 inhibitor of choice in PCI patients requiring OAC. However, concerns have been raised based on the notion that a considerable number of patients may have inadequate response to clopidogrel.
- Trial name
- SWAP-AC-2 (NCT04483583)
- Testing
- Ticagrelor 60mg, Clopidogrel
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Florida
Atrial Fibrillation
Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban
Evaluation of the performance of the 2MACE index in a population of nonvalvular atrial fibrillation (NVAF) patients treated with rivaroxaban in Spain
- Trial name
- EMIR (NCT02975453)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Spain
- Volunteers
- 1,481 people
- Sponsor
- Bayer
Non-Valvular Atrial Fibrillation (NVAF)
A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan
The purpose of this observational study is to understand real-world oral anticoagulants (OAC) (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial fibrillation (NVAF) patients.
- Trial name
- NCT05027061
- Where
- Japan
- Volunteers
- 11,776 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Study of DU-176b Aged 80 Years or Older
The purpose of this study is to evaluate the efficacy and safety of edoxaban in patients with non-valvular NVAF aged 80 years or older who are ineligible for available oral anticoagulation therapy.
- Trial name
- NCT02801669
- Testing
- Du-176b
- Where
- 164 sites in Japan
- Volunteers
- 984 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Atrial Fibrillation
The Effect Of Face-To-Face and Online-Education Provided To İndividuals With Atrial Fibrillation On Medication Adherence and Satisfaction
This randomized controlled study was conducted to investigate the effects of face-to-face Education and tele-education given to individuals with atrial fibrillation taking oral Anticoagulants on their medication compliance and…
- Trial name
- NCT06233721
- Testing
- Online education, Face-to-face education
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Cumhuriyet University
Atrial Fibrillation, Stroke, Ischemic
Use of Oral Anticoagulants and Symptoms in Patients With Atrial Fibrillation in Örebro County
Atrial fibrillation (AF) is the most common sustained arrhythmia and the number of patients with AF is expected to increase substantially in the coming decades.
- Trial name
- NCT04233515
- Testing
- Oral anticoagulant
- Where
- Sweden
- Volunteers
- 11,964 people
- Sponsor
- Region Örebro County
Atrial Fibrillation, Frailty
Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty
The objective of this study is to establish a near-real-time prospective monitoring program in Medicare, Optum and MarketScan Research data to evaluate the benefit of new cardiovascular disease (CVD) drugs for older adults with…
- Conditions
- Atrial Fibrillation, Frailty, Anticoagulant-induced Bleeding, Stroke
- Trial name
- NCT04878497
- Testing
- Warfarin, Dabigatran, Rivaroxaban
- Where
- United States
- Volunteers
- 1,000,000 people
- Sponsor
- Brigham and Women's Hospital
Atrial Fibrillation New Onset
CARDIOLOGIST Trial: Artificial Intelligence Enabled Electrocardiogram for Atrial Fibrillation Detection
This is a randomized controlled trial (RCT) to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of Atrial Fibrillation.
- Trial name
- NCT05127460
- Testing
- AI-enabled ECG-based Screening Tool
- Where
- Taiwan
- Volunteers
- 25,732 people
- Sponsor
- National Defense Medical Center, Taiwan
Deep Venous Thrombosis, Pulmonary Embolism
The DARE Warfarin CER Study
Approximately half a million Americans annually experience venous thromboembolic disease, including deep venous thrombosis (DVT) and pulmonary embolism (PE).
- Trial name
- NCT03271450
- Testing
- Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days)
- Where
- United States
- Volunteers
- 416,000 people
- Sponsor
- Brigham and Women's Hospital
Maternal Complications After Oral Anticoagulation When Initiated Early and Late After Caesarean Section Done for Patients With Mechanical Heart Valve Prosthesis
Early Versus Late Post Caesarean Section Oral Anticoagulation Initiation and Risk of Maternal Complications in Patients With Mechanical Heart Valve Prosthesis
A randomized cohort study applied to patients with mechanical heart valve prosthesis who will be delivered by caesarean section at or after 28 weeks of gestation .
- Trial name
- NCT04855110
- Testing
- Warfarin Sodium started on Day 2 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant), Warfarin Sodium started on day 5 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant)
- Where
- Egypt
- Volunteers
- 114 people
- Sponsor
- Cairo University